Spyre Therapeutics (SYRE) Return on Capital Employed (2016 - 2026)
Spyre Therapeutics posted quarterly Return on Capital Employed of 29.41% for Q1 2026, up 1194.0% year-on-year from 2.27% in Q1 2025, and up 18.26% on a QoQ basis from 35.98% in Q4 2025.
Spyre Therapeutics (SYRE) has 11 years of Return on Capital Employed data on file, last reported at 29.41% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1194.0% year-over-year to 29.41%; the trailing twelve-month figure through Mar 2026 stood at 29.41% (up 1194.0% YoY), and the FY2025 full-year result was 33.03%, up 1650.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.41%, up from 35.98% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 256.36% in Q2 2023 and bottomed at 160.99% in Q1 2023.
- The 5-year median for Return on Capital Employed is 52.08% (2024), against an average of 56.44%.
- The widest annual swing landed in 2023, when Return on Capital Employed soared 36714 bps; it then tumbled 29188 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 127.11% in 2022, then gained by 21 bps to 99.88% in 2023, then soared by 55 bps to 45.27% in 2024, then advanced by 21 bps to 35.98% in 2025, then grew by 18 bps to 29.41% in 2026.
- The last three Return on Capital Employed figures came in at 29.41% (Q1 2026), 35.98% (Q4 2025), and 44.94% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -29.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.41% |
| Dec 31, 2025 | -35.98% |
| Sep 30, 2025 | -44.94% |
| Jun 30, 2025 | -45.02% |
| Mar 31, 2025 | -41.35% |
| Dec 31, 2024 | -45.27% |
| Sep 30, 2024 | -52.08% |
| Jun 30, 2024 | -35.52% |
| Mar 31, 2024 | -72.94% |
| Dec 31, 2023 | -99.88% |
| Sep 30, 2023 | -119.40% |
| Jun 30, 2023 | 256.36% |
| Mar 31, 2023 | -160.99% |
| Dec 31, 2022 | -127.11% |
| Sep 30, 2022 | -105.65% |
| Jun 30, 2022 | -110.78% |
| Mar 31, 2022 | -89.57% |
| Dec 31, 2021 | -66.08% |
| Sep 30, 2021 | -57.81% |
| Jun 30, 2021 | -48.86% |
| Mar 31, 2021 | -61.94% |
| Dec 31, 2020 | -57.31% |
| Sep 30, 2020 | -53.77% |
| Jun 30, 2020 | -82.21% |
| Mar 31, 2020 | -143.72% |
| Dec 31, 2019 | -109.63% |
| Sep 30, 2019 | -78.94% |
| Jun 30, 2019 | -58.03% |
| Mar 31, 2019 | -60.09% |
| Dec 31, 2018 | -70.74% |
| Sep 30, 2018 | -54.11% |
| Jun 30, 2018 | -55.55% |
| Mar 31, 2018 | -62.74% |
| Dec 31, 2017 | -52.56% |
| Sep 30, 2017 | -45.11% |
| Jun 30, 2017 | -41.64% |
| Mar 31, 2017 | -39.31% |
| Dec 31, 2016 | -33.39% |
| Sep 30, 2016 | -28.74% |
| Jun 30, 2016 | -32.94% |
| Mar 31, 2016 | -40.31% |